OliX Pharmaceuticals,Inc
226950.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.38T
Close$
Share Statistics
| Market cap | $2.38 Trillion |
|---|---|
| Enterprise Value | $2.29 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-804 |
| Beta | 0.38 |
| Outstanding Shares | 22,303,319 |
Return
| Return on Equity | -5.93% |
|---|---|
| Return on Assets | -5.12% |
| Return on Invested Capital | -16.28% |
Valuation & Multiples
| P/E Ratio | -194.48 |
|---|---|
| PEG | -1004.15 |
| Price to Sales | 148.94 |
| Price to Book Ratio | 8.55 |
| Enterprise Value to Revenue | 167.98 |
| Enterprise Value to EBIT | -55.1 |
| Enterprise Value to Net Income | -164 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About OliX Pharmaceuticals,Inc
76 employees
CEO: Dong-Ki Lee OliX Pharmaceuticals, Inc. is a biotechnology firm in the clinical development phase, specializing in the creation of RNA interference (RNAi) treatments. Its primary focus lies in developing therapies for various conditions affecting the...